November 28, 2015
Recommended Topic Related To:


"Current prevention strategies have reduced the incidence of HIV worldwide, but that decline has slowed in recent years. We need new prevention strategies if we are to realize President Obama's goal of an AIDS-free generation. Targeting people who"...





Acute overdosage could lead initially to hypoglycemia and subsequently to hyperglycemia.


Long-term overdosage could result in signs and symptoms of acromegaly consistent with the known effects of excess growth hormone.


Acute Critical Illness

Growth hormone therapy should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure. Two placebo-controlled clinical trials in non-growth hormone deficient adult patients (n=522) with these conditions revealed a significant increase in mortality (41.9% vs. 19.3%) among somatropin-treated patients (doses 5.3-8 mg/day) compared to those receiving placebo [see WARNING AND PRECAUTIONS].

Active Malignancy

In general, somatropin is contraindicated in the presence of active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. Somatropin should be discontinued if there is evidence of recurrent activity.

Diabetic Retinopathy

Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.


Serostim® is contraindicated in patients with a known hypersensitivity to somatropin or diluent.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 4/16/2012


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.